Fundz

Enb Therapeutics reported raising $225,000 in an initial SEC Form D filing, from an offering of $1 Million

PRIVATEOct 03, 2023$225K of $1M raised

Amount Raised

$225,000

$225,000 sold, per SEC Form D (first sale Sep 22, 2023)

Round Type

Seed

New YorkBiotechnology

Quick answer

ENB Therapeutics, Inc. raised $225,000 in a Seed round, dated September 22, 2023. ENB Therapeutics, Inc. is based in New York, New York, United States.

How much did ENB Therapeutics, Inc. raise?
ENB Therapeutics, Inc. raised $225,000 in a Seed round on September 22, 2023.
What does ENB Therapeutics, Inc. do?
ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients.
Where is ENB Therapeutics, Inc. based and how big is it?
ENB Therapeutics, Inc. is based in New York, New York, United States.
Who are the decision-makers at ENB Therapeutics, Inc?
Fundz holds 1 contact at ENB Therapeutics, Inc., including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as ENB Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • White River Energy raised $872K (Seed) on November 6, 2023.
  • SLAM BioTherapeutics raised $7.7M on November 3, 2023.
  • Certis Oncology Solutions raised $3.7M (Seed) on November 3, 2023.
  • MyndTec raised $100K (Pre-Seed) on November 3, 2023.
  • Greenbrook TMS raised $2M (Seed) on November 2, 2023.
  • Stellaromics raised $25M (Series A) on November 2, 2023.

Who to call at ENB Therapeutics, Inc., and when

A new round usually means ENB Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day ENB Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ENB Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at ENB Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ENB Therapeutics, Inc.

Location

C/O LAUNCHLABS

New York, New York, United States

About

ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ENB Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsSumayah J., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for ENB Therapeutics, Inc.'s next move

See what Strategic adds

ENB Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.